Novel positron emission tomography approach demonstrates the ability of Immuno-STAT based scaffolds to selectively engage tissue-resident T cells including intratumoral T cells of defined specificity CAMBRIDGE, Mass. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.
CAMBRIDGE, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Baird
CAMBRIDGE, Mass. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the second quarter
CAMBRIDGE, Mass. , Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today a poster presentation featuring
CAMBRIDGE, Mass. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will host a conference call
CUE-101 advances to cohort 5 following Safety Review Committee assessment of expanded cohort 4 Cohort 5 is fully enrolled, with first patient having been dosed on July 20 Additional patients to be enrolled in cohort 4 to further characterize pharmacodynamics and clinical activity in support of
- Novel insights into receptor binding events and interfaces have led to generation of selective molecules with unique biochemical and functional properties through an effort led by Dr. Steven Almo at Albert Einstein College of Medicine - Enhances Cue Biopharma’s ability to engineer molecules for
Patient enrollment and data generation remain on schedule with 13 patients having received CUE-101 to date and enrollment continues per protocol to identify a recommended Phase 2 dose Dose-proportional increases in drug exposure combined with observations demonstrating pharmacodynamic biomarkers
CAMBRIDGE, Mass. , May 28, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Jefferies
CAMBRIDGE, Mass. , May 19, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the first quarter